Summary
A total of 30 patients with recurrent or unresponsive diffuse, aggressive non-Hodgkin's lymphoma, who had previously received doxorubicin, cyclophosphamide, vincristine, and prednisone with or without bleomycin were treated with a combination of doxorubicin, vincristine, ara C, prednisone, and bleomycin (HOAP-Bleo). Complete remissions were achieved in 33.3% of the patients and partial remissions in 13.3%. Four of the ten complete responders relapsed at 4, 10, 11, and 18 months. Myelosuppression was the major toxicity and nonhematological toxicities were acceptable. Their median survival from the date of first relapse was only 4–5 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonadonna G (1985) Chemotherapy of malignant lymphomas. Semin Oncol 12(4) [Suppl 6]: 1–14
Cabanillas F, Hagemeister FB, Bodey GP, Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693–697
Cabanillas F, Burgess MA, Bodey GP, Freireich EJ (1983) Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histologic type. Am J Med 74: 382–388
Carbone PP, Kaplan HS, Mushoff K, Smithiers DW, Tubiana M (1971) Report of the Committee on Hodgkin's Disease Staging. Cancer Res 31: 1860–1861
Fisher RI, De Vita VT, Hubbard SM, Longo DL, Weslely R, Chabner BA, Young RC (1983) Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of ProMace and MOPP chemotherapy. Ann Intern Med 98: 304–309
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
Klimo P, Connors JM (1985) MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102: 596–602
McKelvey EM, Gottlieb JA, Wilson HE, Hant A, Talley RW, Stephens R, Lane M, Gamble JF, Jones SE, Grozea PN, Gutterman J, Coltman C, Moor TE (1976) Hydroxyldaunorubicin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38: 1484–1493
Non-Hodgkin's Lymphoma Pathologic Classification Projects (1982) NCI sponsored study of the classifications of non-Hodgkin's lymphomas. Cancer 49: 2112–2135
Schein PS, DeVita VT Jr, Hubbard S, Chabner BA, Canellos GP, Berard C, Young RC (1976) Bleomycin, adriamycin, cyclophosphamide, vincristine, prednisone (BACOP) combination chemotherapy in the treatment of advanced aggressive histiocytic lymphoma. Ann Intern Med 85: 417–422
Simon R (1986) Confidence intervals for reporting results of clinical trials. Ann Intern Med 105: 429–435
Skarin AT (1986) Diffuse aggressive lymphomas: a curable subset of non-Hodgkin's lymphoma. Semin Oncol 13(4) [Suppl 5]: 10–25
Skarin AT, Canellos GP, Rosenthal DS, Case DC Jr, MacIntyre JM, Pinkus GS, Moloney WC, Frei E III (1983) Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by the use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1: 91–98
WHO (1979) Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48, WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liang, R., Todd, D. & Chan, T.K. HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma. Cancer Chemother. Pharmacol. 22, 169–171 (1988). https://doi.org/10.1007/BF00257316
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257316